InMed Pharmaceuticals Inc.
INM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728328
In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 4 open-market purchases and 0 sales; 20 institutions reported holding it in 13F filings for Q2 2026, worth $5.18M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by InMed Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 4 filings
- 2 insiders, $161.6K in total
- Open-market sells
- 0 filings
- Insiders trading
- 2
- Net value
- +$161.6K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for InMed Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Schneeberger Daniel | 10% Owner | 892,101Indirect | Sep 16, 2026 | 3 |
| ADAR1 Capital Management, LLC | 10% Owner | 892,101Indirect | Sep 16, 2026 | 3 |
| Vivo Opportunity, LLC | 10% Owner | 75,019Indirect | Jul 16, 2026 | 3 |
| Vivo Opportunity Cayman Fund, L.P. | 10% Owner | 75,019Indirect | Jul 16, 2026 | 3 |
| Vivo Opportunity Cayman, LLC | 10% Owner | 75,019Indirect | Jul 16, 2026 | 3 |
| Vivo Opportunity Fund Holdings, L.P. | 10% Owner | 75,019Indirect | Jul 16, 2026 | 3 |
| Klompas Neil A | Director | – | Dec 19, 2025 | 2 |
| Hsu Eric C | Sr. VP, Pre-Clinical Res/Dev | – | Dec 19, 2025 | 2 |
| Adams Eric A | President & CEO | 43,959 | Dec 19, 2025 | 2 |
| Woudenberg Michael | Chief Operating Officer | – | Dec 19, 2025 | 2 |
| Hull Andrew | Director | 38,258 | Dec 19, 2025 | 2 |
| Johnson Shane Aaron | Sr VP & General Manager | 304,595 | Dec 19, 2025 | 1 |
| Lemerond Nicole | Director | – | Dec 19, 2025 | 1 |
| Jagpal Netta | Chief Financial Officer | – | Dec 19, 2025 | 1 |
| Bathery John Steven | Director | – | Dec 19, 2025 | 1 |
| Grove Janet P | Director | – | Dec 23, 2024 | 0 |
| Baldasare Bryan T | Director | – | Dec 23, 2024 | 0 |
| Mancini Alexandra Diane Janet | Other: Consultant | 0 | Aug 2, 2024 | 0 |
| Tegge Jonathan | Interim CFO | – | Dec 26, 2023 | 0 |
| Li Sarah | VP Accounting & Controller | – | Dec 19, 2022 | 0 |
| Garner William J | Director | – | Jan 24, 2022 | 0 |
| Cutler Adam D. | Director | – | Jan 24, 2022 | 0 |
| Colwill Bruce | CFO | 11,515 | Jan 24, 2022 | 0 |
| Sazdanoff Catherine | Director | – | Dec 30, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)6:58 PM ET | Sep 14-16 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +91.1K | $1.30 | +$118.1K | +11.4%892.1K after | 3 lots |
| Jul 17, 2026 (view filing)7:29 PM ET | Jul 15 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +1.00K | $1.56 | +$1.55K | +0.1%801.0K after | |
| Jul 16, 2026 (view filing)9:58 PM ET | Jul 14-16 | 2 days | Vivo Opportunity, LLC and 3 others10% Owner | PPurchase | +20.5K | $1.55 | +$31.8K | +37.7%75.0K after | 6 lots |
| Jul 2, 2026 (view filing)7:02 PM ET | Jun 30-Jul 2 | 2 days | Vivo Opportunity, LLC and 3 others10% Owner | PPurchase | +6.55K | $1.55 | +$10.1K | +9.8%73.1K after | 6 lots |
| Jun 10, 2026 (view filing)9:14 PM ET | May 20-Jun 8 | 21 daysLate | Vivo Opportunity, LLC and 3 others10% Owner | PPurchase | +249.2K | $1.57 | +$391.6K | New position72.5K after | 18 lots |
| May 21, 2026 (view filing)5:08 PM ET | May 19 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +468.6K | $1.54 | +$721.5K | +141.4%800.0K after | 3 lots |
| Aug 2, 2024 (view filing)4:02 PM ET | Jul 31 | 2 days | Mancini Alexandra Diane JanetOther: Consultant | SSale | −240 | $0.1763 | −$42.31 | −100.0%0 after | |
| Feb 22, 2024 (view filing)1:38 PM ET | Feb 21 | 1 day | Hull AndrewDirector | PPurchase | +37.5K | $0.39 | +$14.6K | +4,947.2%38.3K after | |
| Feb 21, 2024 (view filing)2:58 PM ET | Feb 20 | 1 day | Adams Eric APresident & CEO | PPurchase | +41.6K | $0.3587 | +$14.9K | +1,763.5%44.0K after | |
| Apr 18, 2022 (view filing) | Apr 14 | 4 days | Adams Eric APresident & CEO | PPurchase | +14.2K | $0.89 | +$12.6K | +31.6%59.0K after | |
| Apr 13, 2022 (view filing) | Apr 13 | Same day | Adams Eric APresident & CEO | PPurchase | +8.56K | $0.85 | +$7.28K | +23.6%44.8K after | |
| Jan 24, 2022 (view filing) | Jan 24 | Same day | Colwill BruceCFO | PPurchase | +5.00K | $1.09 | +$5.45K | +76.7%11.5K after | |
| Jan 6, 2022 (view filing) | Jan 6 | Same day | Johnson Shane AaronSVP, GM of BayMedica LLC | PPurchase | +8.50K | $1.26 | +$10.7K | +2.9%304.6K after | |
| Dec 30, 2021 (view filing) | Dec 30 | Same day | Johnson Shane AaronSVP, GM of BayMedica LLC | PPurchase | +8.09K | $1.33 | +$10.8K | +2.8%296.1K after | |
| Nov 15, 2021 (view filing) | Nov 15 | Same day | Johnson Shane AaronSVP, GM of BayMedica LLC | PPurchase | +5.00K | $1.37 | +$6.85K | +1.8%288.0K after | |
| Sep 30, 2021 (view filing) | Sep 29 | 1 day | Adams Eric APresident & CEO | PPurchase | +8.80K | $1.73 | +$15.2K | +32.0%36.3K after | |
| Sep 29, 2021 (view filing) | Sep 28 | 1 day | Adams Eric APresident & CEO | PPurchase | +11.4K | $1.75 | +$19.9K | +70.9%27.5K after | |
| Sep 29, 2021 (view filing) | Sep 28 | 1 day | Colwill BruceCFO | PPurchase | +5.00K | $1.77 | +$8.85K | +330.0%6.51K after |